TPG Biologics (6521)

Currency in TWD
25.56
0.00(0.00%)
Closed·
Showing TPG Biologics historical data. For real-time data please try another search
Day's Range
25.5625.56
52 wk Range
0.0025.56
Key Statistics
Bid/Ask
24.70 / 25.59
Prev. Close
25.69
Open
25.56
Day's Range
25.56-25.56
52 wk Range
0-0
Volume
-
Average Volume (3m)
6.76M
1-Year Change
0%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

TPG Biologics Company Profile

As of October 31, 2018, TPG Biologics, Inc. was acquired by Lumosa Therapeutics Co., Ltd. TPG Biologics, Inc., a biotechnology company, researches and develops biologics. The company offers contract research services in the areas of mammalian cell line development and process development. It provides gene construction and transfection, antibody humanization, cell line generation, scalable process development, and protein production and purification services. The company also offers production clones for various biosimilar antibodies, including bevacizumab for the treatment of cancer and eye disease; cetuximab to treat dead, neck, and, colorectal cancer; golimumab and tocilizumab for rheumatoid arthritis; infliximab for the treatment of autoimmune disease; omalizumab for allergic asthma; trastuzumab to treat breast cancer; and ustekinumab for the treatment of psoriasis. In addition, it provides production clone for a biosimilar of thyrotropin alfa. Further, the company develops ECC01, a dual-function fusion protein drug that targets and binds to tumor associated antigens, and converts a non-toxic prodrug into a cytotoxic chemodrug. It has a collaborative research agreement with NanoCarrier Co., Ltd. for the development of antibody/drug-conjugated micelles technology. The company serves companies in Taiwan and internationally. TPG Biologics, Inc. was founded in 2007 and is based in Taipei, Taiwan.

Earnings

Latest Release
Aug 13, 2018
EPS / Forecast
0.35 / --
Revenue / Forecast
35.65M / --
EPS Revisions
Last 90 days

6521 Income Statement

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.